STOCK TITAN

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

Rhea-AI Summary
AbbVie Inc. and OSE Immunotherapeutics collaborate to develop OSE-230, a monoclonal antibody targeting chronic inflammation. OSE to receive $48 million upfront and up to $665 million in milestone payments. AbbVie gains exclusive global license for OSE-230.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
partnership
-
Rhea-AI Summary
AbbVie (ABBV) to participate in the TD Cowen 44th Annual Health Care Conference on March 5, 2024. Key executives to present at 8:10 a.m. Central time. Live webcast and archived session available on AbbVie's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
conferences
-
Rhea-AI Summary
Genmab A/S (GMAB) and AbbVie (ABBV) receive FDA Priority Review for epcoritamab in R/R follicular lymphoma, with a target action date of June 28, 2024. The sBLA submission is based on positive Phase 1/2 EPCORE™ NHL-1 trial results, showing promising treatment responses. Epcoritamab aims to address the unmet needs of difficult-to-treat FL patients, with potential utility across B-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
clinical trial
Rhea-AI Summary
Genmab A/S (GMAB) and AbbVie (ABBV) receive FDA Priority Review for epcoritamab in R/R follicular lymphoma, with a target action date of June 28, 2024. The sBLA submission is based on positive Phase 1/2 EPCORE™ NHL-1 trial results, showing promising treatment responses. Epcoritamab aims to address the unmet needs of difficult-to-treat FL patients, with potential utility across B-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
clinical trial
-
Rhea-AI Summary
AbbVie's epcoritamab-bysp granted Priority Review for the treatment of relapsed or refractory follicular lymphoma, with Breakthrough Therapy Designation by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
Rhea-AI Summary
Cosette Pharmaceuticals, Inc. receives FDA approval for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days exclusivity. The company plans to commence commercial shipments soon, marking a significant milestone in their product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
Rhea-AI Summary
AbbVie Inc. and Tentarix Biotherapeutics have entered into a collaboration to develop novel biologics in oncology and immunology using Tentarix's Tentacles™ platform. AbbVie will have the exclusive option to acquire the therapeutic programs after candidate nomination by Tentarix, with upfront option payments totaling $64 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, launches the 2024 BOTOX® Cosmetic grant program to support women entrepreneurs by providing funding, mentorship, coaching, and community. The program aims to address the Confidence Gap by awarding 20 women entrepreneurs with $25,000 grants to grow their businesses, as women-owned businesses face funding disparities and financial challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
-
Rhea-AI Summary
Richard A. Gonzalez will retire as AbbVie CEO on July 1, 2024, with Robert A. Michael succeeding him. The transition was announced by AbbVie's board of directors, highlighting Michael's leadership capabilities and strategic vision. Gonzalez will become Executive Chairman, ensuring a seamless CEO succession plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
management
Rhea-AI Summary
AbbVie (ABBV) announces 17 accepted abstracts for ECCO 2024, showcasing data on IBD treatments. Key presentations include comparisons of risankizumab and ustekinumab in Crohn's disease, risankizumab maintenance therapy in ulcerative colitis, and long-term safety data on upadacitinib in Crohn's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Abbvie Inc

NYSE:ABBV

ABBV Rankings

ABBV Stock Data

316.04B
1.76B
0.15%
72.06%
0.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.